Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity

  title={Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity},
  author={Jonas Juhl Thomsen and Rikke Louise Rentsch and Paul Robach and J A L Calbet and R Boushel and Peter A. Rasmussen and Carsten Juel and Carsten Lundby},
  journal={European Journal of Applied Physiology},
The effects of recombinant human erythropoietin (rHuEpo) treatment on aerobic power (VO2max) are well documented, but little is known about the effects of rHuEpo on submaximal exercise performance. The present study investigated the effect on performance (ergometer cycling, 20–30 min at 80% of maximal attainable workload), and for this purpose eight subjects received either 5,000 IU rHuEpo or placebo every second day for 14 days, and subsequently a single dose of 5,000 IU/placebo weekly/10… 

The Performance Effects of Microdose Recombinant Human Erythropoietin Administration and Carbon Monoxide Rebreathing

Assessment of the effects on maximal oxygen uptake (V˙O2max) and RSA of two interventions known to differentially influence blood oxygen carrying capacity found that carbon monoxide (CO) inhalation should inhibit RSA.

Mechanism by which rHuEPO improves submaximal exercise performance

  • T. Noakes
  • Medicine
    European Journal of Applied Physiology
  • 2008
If the (submaximal) cardiac output is appropriate so that oxygen supply is indeed optimal during prolonged exercise in healthy humans then, as acknowledged by the authors, rHuEPO administration must improve submaximal endurance performance by mechanisms other than increasing oxygen delivery to the exercising muscles.

Does recombinant human Epo increase exercise capacity by means other than augmenting oxygen transport?

In healthy humans, rHuEpo increases maximal oxygen consumption due to augmented systemic and muscular peak oxygen delivery, and the augmented hematocrit did not compromise peak cardiac output.

Erythropoietin enhances whole body lipid oxidation during prolonged exercise in humans

EPO can modulate substrate utilization during exercise, leading to enhanced fat utilization and lower use of carbohydrates, which opens new research directions exploring whether systemic EPO levels, in physiological conditions, participate to the modulation of fat oxidation.

Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men

Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline, and field performance effects coincided with r HuEpo-induced elevated O2 max and Hbmass.

Effects of human recombinant erythropoietin on endurance performance : real and imagined

The overall aim of this thesis was to determine the effects of administration of recombinant human erythropoietin ( r-HuEpo) on endurance performance and to explore the psychosocial effects of taking this drug and the validity of the Cosmed K4b2 portable metabolic analyser in measuring VO2 during submaximal and maximal running velocities in an outdoor environment.

The Ergogenic Effect of Recombinant Human Erythropoietin on V̇O2max Depends on the Severity of Arterial Hypoxemia

The mechanism highlighted by the data is that besides its strong influence on CaO2, rhEpo was found to enhance leg V̇O2max in normoxia through a preferential redistribution of cardiac output toward the exercising legs, whereas this advantageous effect disappeared during severe hypoxia, leaving augmentedCaO2 alone insufficient for improving peak leg O2 delivery and V̧O2.

Erythropoietin does not reduce plasma lactate, H+, and K+ during intense exercise

In conclusion, rHuEPO does not reduce plasma accumulation of lactate, H+, and K+ at work rates corresponding to ∼80% of peak power output.

Effects of EPO on Blood Parameters and Running Performance in Kenyan Athletes

Four weeks of rHuEpo increased the HGB and HCT of Kenyan endurance runners to a lesser extent than in SCO (~17% vs ~10%, respectively) and these alterations were associated with similar improvements in running performance immediately after the r HuEpo administration and 4 wk after the final injection.

Effects of prolonged recombinant human erythropoietin administration on muscle membrane transport systems and metabolic marker enzymes

Changes in muscle membrane transport proteins and selected muscle enzymes do not contribute to the Epo-induced improvement in performance, and some marker enzymes that are related to aerobic capacity remained unchanged with the treatment.



Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise

The ability of low doses of r-HuEPO to maintain Hct and haematocrit at elevated levels is confirmed.

Effect of rhEPO administration on serum levels of sTfR and cycling performance.

Serum levels of sTfR may be used as an indirect marker of supranormal erythropoiesis up to 1 wk after the administration of rhEPO, but the effects on endurance performance outlast the increase in sTFR.

Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men

In conclusion, low doses of rhEpo increased Hb levels and Hct by more than 10% after 6 weeks, and induced a markedly accentuated blood pressure reaction during exercise.

Effects of recombinant human erythropoietin injections on physical self in endurance athletes

The main psychological result was that endurance athletes were highly sensitive to the effects of rHuEPO on physical fitness and the perception of increased physical condition may lead to a stronger commitment to training.

Effects of erythropoietin administration in training athletes and possible indirect detection in doping control.

A method based on the measurement in blood samples of the sTfR/serum protein ratio to determine if the observed values of this marker are related to rHuEpo abuse is proposed.

Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume

Epo treatment in healthy humans induces an elevation in haemoglobin concentration by two mechanisms: (i) an increase in red cell volume; and (ii) a decrease in plasma volume, which is probably mediated by a downregulation of the rennin–angiotensin–aldosterone axis.

Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers.

A double-blind, placebo-controlled study of the pharmacokinetics and safety of multiple doses of recombinant human erythropoietin in normal male subjects demonstrated that rHuEPO had a dose-related effect on the hematocrit independent of the route of administration and thatmultiple doses of rHu EPO had no direct pressor effects.

Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis.

It is confirmed that r-HuEPO administration causes a predictable and reproducible hematologic response and this work establishes an indirect blood test which offers a useful means of detecting and deterring r- HuEPO abuse.

The effects of red blood cell infusion on 10-km race time.

Erythrocythemia induced by the infusion of 400 mL of autologous packed RBCs effectively increased performance capacity in a 10-km track race, probably due to an increase in oxygen delivery to the working muscles.

Limitations to VO2max in humans after blood retransfusion.